Processa moves 2025 stockholder meeting location

Processa Pharmaceuticals, Inc. reported an update related to its upcoming 2025 Special Meeting of Stockholders.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. reported an update related to its upcoming 2025 Special Meeting of Stockholders. The company had previously filed a proxy statement for this meeting on August 13, 2025. On August 25, 2025, the board of directors decided to change the physical location of the Special Meeting.

The meeting was originally scheduled to be held at the company’s office at 601 21st Street, Suite 300, Vero Beach, Florida. It has now been moved to 594 East Colorado Blvd., Suite 200, Pasadena, California. No changes to the purpose or timing of the Special Meeting are described here, only the change in venue.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Processa Pharmaceuticals (PCSA) disclose in this 8-K?

Processa Pharmaceuticals, Inc. disclosed that its board of directors changed the physical location of the 2025 Special Meeting of Stockholders from Vero Beach, Florida to Pasadena, California, following an earlier proxy statement filed on August 13, 2025.

What is the new location for Processa Pharmaceuticals’ 2025 Special Meeting of Stockholders?

The new location for Processa Pharmaceuticals’ 2025 Special Meeting of Stockholders is 594 East Colorado Blvd., Suite 200, Pasadena, CA 91101.

Where was the Processa Pharmaceuticals 2025 Special Meeting originally scheduled to be held?

The 2025 Special Meeting of Stockholders was originally scheduled to be held at 601 21st Street, Suite 300, Vero Beach, FL 32960, as stated in the previously filed proxy statement.

Did Processa Pharmaceuticals change the date of the 2025 Special Meeting in this filing?

This disclosure only states that the location of the 2025 Special Meeting of Stockholders was changed; it does not describe any change to the date or time of the meeting.

Which SEC rule filing was referenced by Processa Pharmaceuticals for the Special Meeting proxy?

Processa Pharmaceuticals referenced a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934 in connection with its 2025 Special Meeting of Stockholders.

Who signed this Processa Pharmaceuticals 8-K related to the meeting location change?

The 8-K related to the meeting location change was signed on behalf of Processa Pharmaceuticals, Inc. by George Ng, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/25/2025 - 05:21 PM Learn about SEC filing dates

false 0001533743 0001533743 2025-08-25 2025-08-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 25, 2025

Commission file number 001-39531

PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		45-1539785
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

601 21st Street, Suite 300, Vero Beach, FL 32960

(Address of Principal Executive Offices, Including Zip Code)

(772) 453-2899

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock: Par value $.0001		PCSA		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 13, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed a proxy statement (the “Proxy Statement”) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, in connection with its 2025 Special Meeting of Stockholders. On August 25, 2025, the Company’s board of directors changed the location of the Special Meeting of Stockholders from 601 21^st Street, Suite 300, Vero Beach, FL 32960, as set forth in the Proxy Statement, to 594 East Colorado Blvd. Suite 200 Pasadena, CA 91101.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Exhibit Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on August 25, 2025.

	PROCESSA PHARMACEUTICALS, INC.
	Registrant
	By:	/s/ George Ng
		George Ng
		Chief Executive Officer